Modis raises $30M series A for mitochondrial disorders

F-Prime Capital Partners and OrbiMed Advisors led a $30 million series A round for rare genetic disease company Modis Therapeutics Inc. (Oakland, Calif.). The round also included founding investor Aceras Life Sciences and new investor Osage University Partners.